These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 24069538)

  • 1. Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.
    El-Amm J; Freeman A; Patel N; Aragon-Ching JB
    Prostate Cancer; 2013; 2013():210686. PubMed ID: 24069538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer.
    El-Amm J; Aragon-Ching JB
    Clin Med Insights Oncol; 2016; 10(Suppl 1):11-9. PubMed ID: 27042152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasis.
    Wei J; Wang Z; Makarov D; Li X
    Am J Clin Exp Urol; 2013; 1(1):30-8. PubMed ID: 25374898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing bone metastases and reducing skeletal related events in prostate cancer.
    Gartrell BA; Saad F
    Nat Rev Clin Oncol; 2014 Jun; 11(6):335-45. PubMed ID: 24821212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.
    Dorff TB; Agarwal N
    Asian J Androl; 2018; 20(3):215-220. PubMed ID: 29553053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer.
    Saad F; Sternberg CN; Mulders PFA; Niepel D; Tombal BF
    Cancer Treat Rev; 2018 Jul; 68():25-37. PubMed ID: 29787892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art.
    Mollica V; Rizzo A; Rosellini M; Marchetti A; Ricci AD; Cimadamore A; Scarpelli M; Bonucci C; Andrini E; Errani C; Santoni M; Montironi R; Massari F
    Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33535541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases.
    Blacksburg SR; Witten MR; Haas JA
    Curr Treat Options Oncol; 2015 Mar; 16(3):325. PubMed ID: 25777571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting bone metastases in prostate cancer: improving clinical outcome.
    Body JJ; Casimiro S; Costa L
    Nat Rev Urol; 2015 Jun; 12(6):340-56. PubMed ID: 26119830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
    Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
    Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologic fracture in patients with metastatic prostate cancer.
    Gartrell BA; Saad F
    Curr Opin Urol; 2014 Nov; 24(6):595-600. PubMed ID: 25166424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revisiting the role of bone-modifying agents in the management of metastatic prostate cancer.
    Cheung FY
    Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():13-15. PubMed ID: 30489032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
    Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M
    Cancer Treat Rev; 2016 Mar; 44():61-73. PubMed ID: 26907461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.
    Miller K; Steger GG; Niepel D; Lüftner D
    Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):461-472. PubMed ID: 29988100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing skeletal-related events prevention in patients with advanced prostate cancer.
    Leung AK
    Asia Pac J Clin Oncol; 2020 Sep; 16 Suppl 3():4-6. PubMed ID: 32852902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
    Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radium-223 for the treatment of castration-resistant prostate cancer.
    El-Amm J; Aragon-Ching JB
    Onco Targets Ther; 2015; 8():1103-9. PubMed ID: 26056474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?
    Gómez Rivas J; Carrion DM; Alvarez-Maestro M; Cathelineau X; Sanchez-Salas R; Di Lorenzo G; Di Maio M; Paul A; Martinez-Piñeiro L; Sartor O; Saad F; Debruyne F
    Minerva Urol Nefrol; 2019 Oct; 71(5):445-456. PubMed ID: 31353876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.
    Picciotto M; Franchina T; Russo A; Ricciardi GRR; Provazza G; Sava S; Baldari S; Caffo O; Adamo V
    Expert Opin Pharmacother; 2017 Jun; 18(9):899-908. PubMed ID: 28449621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.